drugset

drugset / Trial / NCT07424677

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

NCT07424677 ↗

Phase 3 Not yet recruiting 89 enrolled Zydus Therapeutics Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy

Timeline

Start: 2026-06
Primary completion: 2028-07
Completion: 2028-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Saroglitazar	Small molecule	1 mg	Oral

Indications